Proteomic analysis of bone cancer: A review of current and future developments

Expert Review of Proteomics

Volumn 4, Issue 3, 2007, Pages 371-378

  Bhattacharyya, Sudeepa ^a   Byrum, Stephanie ^a   Siegel, Eric R ^b   Suva, Larry J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Biomarker; Data analysis; Expression profiling; Metastasis; Osteolysis; SELDI TOF MS; Skeletal malignancy; Tandem mass spectrometry

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

BONE CANCER; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; GENE EXPRESSION PROFILING; HUMAN; METASTASIS; MULTIPLE MYELOMA; OSTEOSARCOMA; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; REVIEW; STATISTICAL SIGNIFICANCE;

BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FORECASTING; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249994549     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.3.371     Document Type: Review

References (61)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593 (2002). •• Excellent review of the current state of bone cancer biology.
2. Fidler I, Poste G. The pathogenesis of cancer metastasis. Nature 283, 139-146 (1979). • Classic discussion of the physiology of metastasis, the foundation of our understanding.
3. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3, 453-458 (2003).
4. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 127, 679-695 (2006).
5. Marguiles AG, Klimberg VS, Bhattacharrya S, Gaddy D, Suva LJ. Genomics and proteomics of bone cancer. Clin. Cancer Res. 12, S6217-S6221 (2006).
6. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11, 76-81 (2005). • Excellent review of the complexities of bone cell biology.
7. Guise TA, Kozlow WM, Heras-Herzig A et al. Molecular mechanisms of breast cancer metastases to bone. Clin. Breast Cancer 5(Suppl.2), S46-S53 (2005).
8. Bendre M, Gaddy D, Nicholas RW, Suva LJ. Breast cancer metastasis to bone: it is not all about PTHrP. Clin. Orthop. Relat. Res. 415(Suppl.), S39-S45 (2003).
9. Guise TA, Mohammad KS, Clines G et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 12, S6213-S6216 (2006).
10. Minn AJ, Kang Y, Serganova I et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 115, 44-55 (2005).
11. Kang Y, Siegel PM, Shu W et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
12. Massague J. Sorting out breast-cancer gene signatures. N. Engl. J. Med. 356, 294-297 (2007).
13. Peyruchaud O, Winding B, Pecheur I et al. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J. Bone Miner. Res.16, 2027-2034 (2001).
14. Yoneda T, Williams P, Hiraga T, Niewolna M, Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental breast cancer cells and a brain-seeking clone in vivo and in vitro. J. Bone Miner. Res.16, 1486-1495 (2001).
15. Bendre MS, Gaddy-Kurten D, Mon-Foote T et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 62, 5571-5579 (2002).
16. Tian E, Zhan F, Walker R et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483-2494 (2003).
17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57-70 (2000). •• Excellent review of the current understanding of cancer cell biology.
18. Simpkins F, Czechowicz JA, Liotta L, Kohn EC. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. Pharmacogenomics 6, 647-653 (2005).
19. Hortin GL, Jortani SA, Ritchie JC Jr, Valdes R Jr, Chan DW. Proteomics: a new diagnostic frontier. Clin. Chem. 52, 1218-1222 (2006).
20. Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: a review. Crit. Rev. Oncol. Hematol. 56, 365-378 (2005).
21. Lipton A. Management of bone metastases in breast cancer. Curr. Treat. Options Oncol. 6, 161-171 (2005).
22. Verrills NM. Clinical proteomics: present and future prospects. Clin. Biochem. Rev. 27, 99-116 (2006).
23. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 52, 1223-1237 (2006). • Review of the current mass spectrometry-based view of the plasma proteome.
24. Lim MS, Elenitoba-Johnson KS. Proteomics in pathology research. Lab. Invest. 84, 1227-1244 (2004).
25. Li L, Tang H, Wu Z et al. Data mining techniques for cancer detection using serum proteomic profiling. Artif. Intell. Med. 32, 71-83 (2004). •• Important discussion of the data mining and bioinformatic approaches critical to biomarker identification and validation.
26. von Haller PD, Yi E, Donohoe S et al. The application of new software tools to quantitative protein profiling via isotope-coded affinity tag (ICAT) and tandem mass spectrometry: II. Evaluation of tandem mass spectrometry methodologies for large-scale protein analysis, and the application of statistical tools for data analysis and interpretation. Mol. Cell Proteomics 2, 428-442 (2003).
27. Paik YK, Jeong SK, Lee EY, Jeong PY, Shim YH. C. elegans: an invaluable model organism for the proteomics studies of the cholesterol-mediated signaling pathway. Expert Rev. Proteomics 3, 439-453 (2006).
28. Wittmann-Liebold B, Graack HR, Pohl T. Two-dimensional gel electrophoresis as tool for proteomics studies in combination with protein identification by mass spectrometry. Proteomics 6, 4688-4703 (2006).
29. Calvo KR, Liotta LA, Petricoin EF. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci. Rep. 25, 107-125 (2005). •• Outstanding discussion of the process of biomarker discovery and the introduction of personalized medicine approaches.
30. Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin EF III. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J. Pathol. 208, 595-606 (2006).
31. Petricoin EF, Liotta LA. Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin. Chem. 49, 533-534 (2003).
32. Chertov O, Simpson JT, Biragyn A et al. Enrichment of low-molecular-weight proteins from biofluids for biomarker discovery. Expert Rev. Proteomics 2, 139-145 (2005).
33. Liotta LA, Kohn EC. Cancer's deadly signature. Nat. Genet. 33, 10-11 (2003).
34. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002).
35. Wulfkuhle JD, Liotta LA, Petricoin EF. Early detection: proteomic applications for the early detection of cancer. Nat. Rev. Cancer 3, 267-275 (2003).
36. Rosty C, Christa L, Kuzdzal S et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis- associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 62, 1868-1875 (2002).
37. Bhattacharyya S, Siegel ER, Petersen GM et al. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 6, 674-686, (2004).
38. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ. Proteomic patterns: their potential for disease diagnosis. Mol. Cell. Endocrinol.230, 95-106 (2005).
39. Brown RE, Boyle JL. Mesenchymal chondrosarcoma: molecular characterization by a proteomic approach, with morphogenic and therapeutic implications. Ann. Clin. Lab. Sci. 33, 131-141 (2003).
40. Kohli M, Siegel E, Bhattacharya S et al. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark. 2, 249-258 (2006).
41. Bhattacharyya S, Epstein J, Suva LJ. Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools. Dis. Markers 22, 245-255 (2006).
42. Li Y, Dang TA, Shen J et al. Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics 6, 3426-3435 (2006).
43. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr. Opin. Biotechnol. 15, 24-30 (2004).
44. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev. Cancer 6, 961-967 (2006). • The first discussion of the carrier proteins involved in low-molecular-weight proteome.
45. Newling DW, Denis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer - Genitourinary Group Study 30853. Cancer 72, 3793-3798 (1993).
46. Le L, Chi K, Tyldesley S et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin. Chem. 51, 695-707 (2005).
47. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin. Cancer Res. 11, 8006-8014 (2005).
48. Roodman GD. Biology of osteoclast activation in cancer. J. Clin. Oncol. 19, 3562-3571 (2001).
49. Bendre MS, Margulies AG, Walser B et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway. Cancer Res. 65, 11001-11009 (2005).
50. Benoy IH, Salgado R, Van Dam P et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 10, 7157-7162 (2004).
51. Uehara H, Troncoso P, Johnston D et al. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64, 40-49 (2005).
52. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl Cancer Inst. 96, 353-356 (2004).
53. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem. 49, 1272-1275 (2003).
54. Liotta LA, Lowenthal M, Mehta A et al. Importance of communication between producers and consumers of publicly available experimental data. J. Natl Cancer Inst. 97, 310-314 (2005).
55. Rai AJ, Stemmer PM, Zhang Z et al. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 5, 3467-3474 (2005). •• Important paper documenting the reliability of SELDI-TOF-derived protein biomarker signatures across institutions.
56. Anderson NL, Anderson NG. The human plasma proteome: history, character and diagnostic prospects. Mol. Cell Proteomics 1, 845-867 (2002).
57. Ward JB Jr, Henderson RE. Identification of needs in biomarker research. Environ. Health Perspect.104(Suppl.5), 895-900 (1996).
58. Shi L, Reid LH, Jones WD et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151-1161 (2006).
59. Minor JM. Microarray quality control. Meth. Enzymol. 411, 233-255 (2006).
60. Bouamrani A, Ternier J, Ratel D et al. Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics. Clin. Chem. 252, 2103-6 (2006).
61. HUPO: Human Proteome Organisation www.hupo.org